The most common grade 3/4 AEs in the overall 58 expansion-phase patients (including the triplet therapy cohort and HR+ HER2− PIK3CA unselected cohort and an ER-negative PIK3CA mutant breast cancer or other solid tumor cohort) were neutropenia (53%) and leukopenia (21%). This evidence concerns the gene ERBB2 and breast carcinoma.